DLX4 is a homeobox transcription factor located on chromosome 17-q22 that functions as a sequence-specific DNA-binding regulator of gene expression 1. Primary functions include controlling hematopoietic lineage commitment and developmental processes. DLX4 promotes megakaryocyte differentiation while suppressing erythroid development through IL-1β and NF-κB signaling activation 2. During embryonic development, DLX4 participates in palatogenesis and craniofacial development 3. DLX4 also enhances reprogramming of human dental pulp cells into induced pluripotent stem cells, functionally replacing c-MYC in combination with OCT3/4, SOX2, and KLF4 4. In normal physiology, DLX4 expression is cycle-dependent in the endometrium, with higher levels during the proliferative phase, suggesting roles in epithelial-mesenchymal cell interactions 5. Disease relevance includes associations with fetal growth restriction, where elevated placental DLX4 expression correlates with developmental abnormalities 6. In cancer, BP1 (a DLX4 isoform) overexpression in endometrial carcinoma promotes cell proliferation and migration while predicting poor prognosis 7. Nuclear DLX4 immunoreactivity is reduced in breast carcinomas compared to normal tissue 8. Non-syndromic orofacial clefts associate with DLX4 mutations, though population variants show limited independent association 3.